Last reviewed · How we verify
TRK-100STP
At a glance
| Generic name | TRK-100STP |
|---|---|
| Also known as | beraprost, Careload LA, YM533 |
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) (PHASE2)
- TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) (PHASE2, PHASE3)
- A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment (PHASE1)
- Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males (PHASE1)
- Drug-Drug Interaction Study of TRK-100STP (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRK-100STP CI brief — competitive landscape report
- TRK-100STP updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI